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Abstract
Mobile phones and other remote monitoring devices, collectively referred to as "mHealth," promise to transform the treatment
of a range of conditions, including movement disorders, such as Parkinson’s disease. In this viewpoint paper, we use Parkinson’s
disease as an example, although most considerations discussed below are valid for a wide variety of conditions. The ability to
easily collect vast arrays of personal data over long periods will give clinicians and researchers unique insights into disease
treatment and progression. These capabilities also pose new ethical challenges that health care professionals will need to manage
if this promise is to be realized with minimal risk of harm. These challenges include privacy protection when anonymity is not
always possible, minimization of third-party uses of mHealth data, informing patients of complex risks when obtaining consent,
managing data in ways that maximize benefit while minimizing the potential for disclosure to third parties, careful communication
of clinically relevant information gleaned via mHealth technologies, and rigorous evaluation and regulation of mHealth products
before widespread use. Given the complex array of symptoms and differences in comfort and literacy with technology, it is likely
that these solutions will need to be individualized. It is therefore critical that developers of mHealth apps engage with patients
throughout the development process to ensure that the technology meets their needs. These challenges will be best met through
early and ongoing engagement with patients and other relevant stakeholders.
(JMIR mHealth uHealth 2015;3(4):e95)  doi: 10.2196/mhealth.4538
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Introduction
Mobile phones are an increasingly common form of information
and communication technology that combine mobile computing
capabilities with telecommunications [1]. In 2011, there were
over 6 billion cell and mobile phone subscriptions reaching 87%
of the world’s population [2]; 1 in 3 subscriptions were for a
mobile phone [3]. The ability to run third-party software apps
on mobile phones has prompted their use in health settings to
improve diagnosis and personalize health care [1]. This use of
mobile phone technologies for this purpose has been termed
“mHealth.”
Mobile phone apps may support an individual’s self-report of
symptoms or passively record time, location, and other
information using a large array of on-board instruments, such
as a global positioning system (GPS), wireless local area
network (WLAN; or Wi-Fi), cellular network antennae,
Bluetooth, accelerometers, gyroscopes, pressure sensors,
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proximity-sensing magnetometers, barometers, humidity sensors,
temperature sensors, and ambient light sensors [4]. Microphones
and cameras may also record images and sounds in the vicinity
of the phone, including personal conversations [5]. Additional
external sensors may allow recording of physiological
information, such as heart rate, blood pressure, glucose levels,
and even brain activity using a portable brain scanner (eg,
electroencephalogram) [6]. This information can be linked to
other commercially available electronic databases, including
Web-based platforms (eg, Facebook, Google) or
government-controlled personal medical records. Algorithms
may be used to organize and decode the recorded information
to provide data on disease state, response to treatment, physical
activity levels, falls, and tremor. Mobile phones can then send
this information to research or clinical teams, which enables
timely responses that were not possible using older technologies
[4].
mHealth technologies are being increasingly used to help
patients manage chronic, degenerative neurological diseases,
such as Parkinson’s disease (PD), that produce changes in
mobility, communication, mood, and independence. In the
following, we use PD as an example, although most
considerations discussed below are valid for a wide variety of
conditions. Mobile phones and other remote sensing devices
have been used with people with PD to monitor their movement
at home [7-9], hand tremor [10], timing of medication and meals
[7], community mobility [11], and voice patterns [12].
The ability to remotely monitor a wide range of markers of
social well-being in PD is increasingly important. Medications
and other treatments, such as deep brain stimulation, can
improve the motor symptoms of people with PD, but these
medications and treatments may not be accompanied by similar
improvements in the nonmotor symptoms and quality of life
outcomes [11]. Mobile phones have the potential to measure
both motor and nonmotor symptoms in PD, and they can analyze
large amounts of data before providing summary reports to the
patient and his or her physician to guide treatment decisions
[13]. The capacity of mobile phones to collect a wide range and
quantity of personal information from patients raises novel and
complex ethical and practical challenges that research teams
and clinicians need to understand if we are to maximize the
promise of the technology while minimizing any unintended
harms. Analogous concerns have been examined in the context
of Internet research and eHealth [14-17]. Given the additional
capacity of mobile phones to collect personal information and
the explosion in mHealth apps, an examination of the ethical
challenges raised by the use of mobile phones in the research
and treatment of persons with major neurodegenerative
disorders, such as PD, is urgently needed.
Ethical Issues Raised by the Use of
Mobile Phones for Research and in the
Clinic
Privacy, Security, and Data Ownership
Privacy is the ability to control the recording and sharing of
personal information with others. This requires knowledge of
what will be recorded, how it will be used and for how long,
who will have access to this information, and what the risks are
of discovery and misuse by third parties.
What Can Mobile Phones Reveal About a Person?
Geolocation technologies on a mobile phone (eg, GPS, WLAN)
can reveal a range of personal information. This might include
where you live, where your children go to school, whether you
visit a therapist and if so how often, how often you visit drinking
or gambling establishments, whether you arrive early or late to
work, whether you have participated in a protest or are
associated with outlawed or terrorist organizations, and other
habits or routines [5,18-20]. It is possible to identify a specific
individual with reasonable certainty from this information.
Consequently, it may be impossible to deidentify an individual’s
mobile phone data, the standard way of protecting personal
privacy in research. This may be of particular relevance in PD
where up to 1 in 6 patients will develop severe compulsive
disorders (eg, pathological gambling, hypersexuality,
compulsive shopping) as a result of their dopamine replacement
therapy [21]. These behaviors can cause substantial harm to
others and may come to the attention of relevant government
authorities, which could then lead to criminal or civil suits [22].
The difficulty in anonymizing mobile phone data is particularly
salient in a global research environment that increasingly
requires the sharing of data in publicly available repositories.
The greatest threat to privacy is third-party use of data recorded,
collected, and transmitted by a mobile phone. Data may come
into the hands of a third party via hacking of information sent
over the Internet or via Bluetooth (commonly referred to as
“sniffing”); legal interception by government agencies (eg,
subpoena); incidental discovery by someone accessing the
phone; or by telecommunication companies and cloud storage
providers, for example, Internet service provider (ISP), Google,
Amazon, who may claim ownership of the data recorded by or
transmitted through their networks [23].
Subpoena and Government Interception
Researchers and clinicians can only provide limited guarantees
on privacy protection. For instance, data collected on mobile
phones may be subpoenaed as part of legal proceedings in civil
(eg, divorce, litigation) or criminal cases. This includes both
the data collected on the phone itself or data and their analysis
held by researchers or clinicians. Researchers and clinicians are
obliged to hand over such private information when subpoenaed.
Mobile phones are more prominent in the public domain than
in traditional office-based pen-and-paper or desktop computer
research kept within the offices of researchers or clinicians. The
information collected via mobile phones is more liable to be
encountered by third parties who are not involved in the research
or clinical care. The legal subpoena of clinical data is possible
within any research setting. However, a person’s participation
in a research study is more likely to become known to authorities
through the presence of an app on their mobile phone [20]. The
simple discovery of an mHealth app on a phone may be enough
to disclose personal information that users may wish to keep
private, such as their having a neurodegenerative disorder or
medication-induced addiction.
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Hacking and Third-Party Data Ownership
The security of data collected via mobile phones cannot be
guaranteed. Hacking of personal data from mHealth apps has
resulted in medical identity theft and significant financial losses
[23], and such data have been used in the courts [24]. mHealth
apps are not required to adhere to strict privacy regulations,
such as the US Health Insurance Portability and Accountability
Act Privacy Rule, and therefore may be stored and transferred
using methods that are less secure than those normally required
of electronic medical data [23]. The data transmitted may
include usernames, passwords, and other personal information
that may enable forms of identity theft.
Encryption is essential for the storage and transmission of data
using mobile phones; however, a recent study found that many
mHealth apps do not use encryption when transferring data [23].
Even with modern encryption methods, data may be accessible
to hackers and/or government authorities. The recent incidences
of high-profile mobile phone hacking in the United States and
United Kingdom illustrate the vulnerability of mobile phone
users to privacy violations [25]. There are also potential privacy
violations from computer malware and virus programs that
exploit vulnerabilities in how data are stored on the device or
from malevolent app developers who steal data for commercial
or criminal interests [23,26]. Developers can take steps to ensure
that data collected by an mHealth app are not available (eg, via
data logs, SD card storage, exported, and side channels) to other
apps or programs contained on the phone [23]. As He et al [23]
demonstrate, most mHealth apps currently available do not take
the necessary security measures to protect an individual’s
privacy.
It is also not clear who owns the data in research and clinical
settings. Mobile phone data may be transmitted to the research
team or clinician via ISP or telecommunication companies.
These companies often record metadata as well as the data
transferred over their networks, and may sell them to other third
parties. Government agencies may also obtain access to this
information, as revealed by Edward Snowden in the recent
National Security Agency affair [27].
Obtaining Informed Consent
Before using mHealth technologies, clinicians and researchers
need to seek and obtain the informed consent from participants.
Participants need to be informed of the risks and benefits of
using mHealth technologies and must have the capacity to
understand these risks and make a free and uncoerced decision
about whether to participate [28]. A challenge in mHealth is
communicating the complex nature of the risks raised by this
technology and negotiating the risks that individuals are willing
to face. How much input should people have over what they
wish to have recorded and shared? How will the data be used,
where will it be stored and in what form, how will it be shared,
and for how long? Participants must also be made aware of what
will happen to their data once their study participation is
complete.
Researchers and clinicians using mobile phone technologies
need to develop consent processes that actively engage
individuals in their own privacy decision making as much as
possible. Understanding the risks posed by third-party access
to their personal health data can be difficult to communicate
given the complexity of mHealth technologies. Meeting these
ethical challenges will require technology developers to create
apps that assist participants in understanding their participation
and give them as much say as possible in what is shared and
with whom. This may involve trade-offs between, on the one
hand, maximizing the data obtained and what may be done with
it, and, on the other hand, enabling participants to control what
they consent to and how their data may be used and stored.
As part of the consent process, researchers and clinicians need
to inform participants about the circumstances in which they
are obliged to disclose the participants’ personal information.
This potentially includes information that can pose an immediate
and likely threat to themselves or to others (eg, suicide,
homicide). Patients must also be informed of the potential for
identification of “incidental findings,” specifically clinically
significant information related to their health, such as cognitive
impairment and dementia, depression and other psychiatric
disorders, or medication abuse or other compulsive behaviors
that may benefit from additional treatment. Patients should be
informed about the processes in place to deal with potential
incidental findings and provide them with further information
and access to clinical treatment should any emerge. Participants
should also be given the opportunity to indicate whether they
would like to be told about the presence or absence of incidental
findings.
The potential for mobile phones to record conversations about
third parties or bystanders raises additional ethical and legal
concerns. For example, mobile phones may record conversations
to examine the impact of PD on patients’ speech and
socialization [11,12]. Researchers may obtain consent from the
research participant to have their conversations recorded but
they cannot easily obtain consent from bystanders (eg, friends
and family) who may also be recorded via the mobile phone.
The recording and/or communicating of third-party
conversations (even to a secure portal) is illegal in some
jurisdictions. Researchers may therefore need to develop
methods for ensuring that bystanders are able to consent to
having their conversations recorded. One option would be to
provide an alert on the mobile phone indicating to the participant
that a recent conversation has been audio recorded so that they
can ask third parties to consent to the recording. An opt-in
approach could be applied where the conversation is only sent
to researchers or clinicians if the third-party individuals agree.
This would further burden the participant who would have to
disclose their mHealth participation and, therefore, possibly
their clinical condition to obtain the third party’s consent. The
opt-in approach also obtains consent after the fact, and therefore,
may be inadequate in some jurisdictions.
Storing and Sharing Mobile Phone Data
How mobile phone data are stored and shared can have
important implications for privacy risk. Developers may choose
to create a secure “vault” on the device that is physically
transferred to researchers or clinicians at predetermined
intervals. This allows greater control of data and protection for
participants, but at the cost of reduced flexibility and timeliness.
JMIR mHealth uHealth 2015 | vol. 3 | iss. 4 | e95 | p. 3http://mhealth.jmir.org/2015/4/e95/
(page number not for citation purposes)
Carter et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
It could limit the benefits that a patient or participant may derive
from the ability to self-manage their condition.
The most clinically and scientifically useful approach is to
periodically upload the data electronically (eg, via 3G or
wireless networks) to researchers or clinicians. This allows for
instantaneous transfer of data, but provides less privacy
protections as it involves transmitting data over third-party
networks. Developers will need to decide where and when data
are uploaded (eg, only at certain locations or times, such as from
a home Wi-Fi network) as opposed to routinely uploading via
public Wi-Fi or mobile networks. Developers will need to reach
a balance between maximizing clinical or scientific utility while
minimizing the risk to privacy. Solutions will vary depending
on how the technology is being employed.
Developers will also need to consider what data to collect and
transmit from the mobile phone. The ability to collect as much
raw data as possible maximizes the information that a research
and clinical team can extract. It also increases the potential risk
to the participant. A balance needs to be struck between
maximizing scientific and clinical utility and protecting privacy.
It is preferable to only collect data sufficient for the purpose of
the study or clinical intervention (eg, postcode or distance from
home), rather than collecting all data routinely. By collecting
only the minimum amount of information, app developers can
help participants maintain control over their raw data [20].
Developers also need to make data comprehensible to the
participant before they are sent or before consent is given to
share the data. Developers should provide easily understandable
visual information to participants about where their information
will go, who will have access to it, and for how long. This will
greatly increase participants’ understanding of the risks involved
with this technology and enable them to make more informed
decisions. Such processes will help participants to see what
their sharing policies are and what the results of these policies
will be [20].
Communication of Clinical or Research Results
A critical decision in the clinical or research use of mobile
phones is when and what to tell research participants or patients
about their data. The communication of clinically meaningful
feedback to participants about their data maximizes the benefits
for participants and mitigates the harm from potential privacy
violations. To be clinically meaningful, the findings must be
scientifically robust. The ethical obligation to share an
individual’s data with them is more acute in the clinical setting
where the explicit aim is to facilitate better clinical management
of the disease, and there is strong evidence to support the clinical
claims being made. Feedback is also provided by a qualified
individual responsible for the patient’s clinical management.
In research, the clinical relevance of data is, by definition, less
certain because the research aim is to establish an evidence base
for clinical intervention. In research, providing individualized
clinical feedback from the data is inappropriate, and may lead
to additional harm if the clinical advice is misleading or
provided by nonprofessionals.
The provision of immediate and useful information by
appropriately qualified clinicians can potentially better enable
individuals to manage their health and improve the
clinician/patient relationship by empowering patients to take
more control over their health and well-being [29,30]. However,
to serve this purpose the information collected by the mobile
phone needs to be presented in ways that are meaningful,
accurate, and easily understood. Well-designed platforms that
provide such feedback to patients will maximize the potential
for individuals to self-manage their health and well-being.
Participants may also be assisted to access effective clinical
services for the treatment of any symptoms identified in the
data collected via their mobile phone. Developers and
researchers may also wish to identify opportunities in the app
in which participants can receive information that will enable
them to make healthier choices. Research is needed to establish
what impact the provision of clinical information recorded on
mobile phones may have on a person’s behavior.
Communication of deteriorating motor symptoms, for example,
could adversely impact on well-being and health-related
behaviors. See Eonta et al [31] for practical guidance on the
ethical communication of clinical information to patients using
mobile phones and other mHealth technologies.
Access to mHealth Technology
While there has been a rapid growth in mobile phone coverage
in recent years, some segments of the population lack access.
People from lower socioeconomic groups may not be able to
afford a phone capable of supporting the app or connecting with
mobile or Internet networks required to transmit potentially
large volumes of data. There is an ethical imperative not to
exclude these patients from benefiting from mHealth monitoring.
Disease-related impairments may also interfere with the effective
use of these technologies. PD may impair both fine motor and
speech skills, therefore creating difficulty in accessing touch
screens or voice-based interaction with mobile phones.
Designers of mHealth apps must consider ways of reducing the
effects of these cognitive, motor, or other impairments. Having
a choice on how to interact with an app is one approach (eg,
voice-activated, image- or text-based interface). People with
PD who experience fine motor difficulties may be assisted by
reducing the sensitivity of the screen to repeated touch,
appropriate spacing and sizing of buttons, use of swipe on-screen
keyboard, and external devices such as a stylus. People with
voice-related difficulties may be assisted by a plug-in
microphone and software that can be trained to an individual’s
voice (eg, Dragon Dictate).
Given the complex array of symptoms and differences in
comfort and literacy with technology, it is likely that these
solutions will need to be individualized. It is therefore critical
that developers of mHealth apps engage with patients throughout
the development process to ensure that the technology meets
their needs. This will assist developers, clinicians, and research
teams to target the symptoms that are of greatest concern to
patients. Developers should use reference groups (eg, consumer,
family, industry, health care professional) to anticipate
challenges in developing technology that meets these challenges
[11]. As one patient reported in regard to the use of mobile
phones for diabetes, “It’s not just about blood glucose results
and HbA1c results, it’s about how people feel and, perhaps,
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how their mood may affect their glucose levels” [29]. A
summary of the recommendations for managing these ethical
challenges is presented in Table 1.
Table 1. Ethical recommendations for the use of mobile phones in the clinic and laboratory.
RecommendationEthical issue
In many cases, deidentification is not possible. Developers must communicate this to users when obtaining
consent.
Anonymity and de-identification
Individuals should be informed about the risk of third parties accessing data collected on mobile phones, either
via hacking, legal interception (eg, subpoena), incidental discovery by someone accessing the phone, or by
telecommunication companies (eg, ISP provider, Google) that may claim ownership of the data recorded by or
transmitted through their networks.
Third-party use of data
The risk of privacy violations can be minimized by thoughtful consideration of how the data are stored locally
on the phone or transmitted to the research or clinical team. Apps can be placed in secure vaults on mobile
phones to minimize incidental discovery. Developers should also record and transmit the minimal amount of
data necessary for the purpose of the app.
Storage and transmission of data
Participants need to be informed about the risks and benefits of using mHealth technologies and must have the
capacity to understand these risks and make a free and uncoerced decision about whether to participate. Re-
searchers and clinicians should employ visual aids that communicate the complex nature of the risks posed by
mHealth. Developers should maximize opportunities for users to control what data are shared with the clinical/re-
search team, such as through the use of pop-up messages asking whether they consent to specific information
being shared.
Obtaining informed consent
Feedback of clinically relevant information should be provided by a qualified health care professional and when
there is strong empirical evidence to support the findings. Users should be informed at the point of consent what
information may be uncovered by mobile phones and whether they will be informed about these findings. Patients
should also be assisted with accessing necessary clinical services as a result of the findings.
Communication of clinically rele-
vant results
Efforts should be undertaken to prevent individuals benefiting from advances in mHealth as a result of their
socioeconomic status or physical or mental impairments.
Access to mHealth technologies
Developers should use reference groups (eg, consumer, family, industry, health care professional) throughout
the development process to ensure that the technology meets participants’ needs.
Active engagement with patients
mHealth technologies should be rigorously evaluated to demonstrate their safety and effectiveness before the
widespread rolling out of mHealth apps and associated products.
Regulation of mHealth products
Regulating and Evaluating mHealth Apps and
Products
An explosion in mHealth research [32] has led to a rapid
proliferation of small pilot or seed programs, many of which
lack scientific evidence of efficacy on which to base clinical
use. There is limited evidence on the effectiveness, or safety,
of mHealth apps as a self-management tool for improving health
[29]. Hence, there is an urgent need to evaluate their
effectiveness via randomized controlled trials before the
widespread rollout of mHealth apps and associated products
(eg, brain or heart monitors) [33]. This need was recognized by
the World Health Organization and other leading agencies
responsible for implementing medical products in the Bellagio
call to action on global eHealth evaluation that called for
rigorous evaluation “to generate evidence and promote the
appropriate integration and use of technologies...to improve
health and reduce health inequalities” [34].
It is imperative that the use of mHealth apps by researchers,
clinicians, universities, and hospitals is based on rigorous
evaluations of their effectiveness and safety [29], using the
CONSORT-EHEALTH checklist [35] and GRADE framework
[32]. Policy makers should not be seduced by the hype and
promise of mHealth technology. The prima facie simplicity and
cost effectiveness of mHealth solutions may blind decision
makers to the lack of robust empirical evidence that is needed
to justify their routine use [29]. Premature implementation of
untested mHealth interventions may result in failed projects,
wasted resources, and poorer health outcomes for patients.
There is currently no regulation of mHealth devices or apps and
no guarantee that they provide clinically accurate information.
The Food and Drug Administration (FDA) recently released
guidelines for how they intend to regulate the marketing of
mHealth apps that meet the definition of medical devices (ie,
those “whose functionality could pose a risk to a patient’s safety
if the mobile app were to not function as intended”) [36],
although these recommendations are currently nonbinding and
do not prevent apps from being made available. The FDA has
recently approved the marketing of an mHealth app to
continuously monitor glucose levels [36].
However, most apps are made available to patients directly via
publicly available app stores, without passing through regulatory
gatekeepers to ensure their safety and effectiveness. The clinical
use of these devices and apps needs to be regulated in the same
way as any other medical or psychotherapeutic intervention.
This is particularly important given the influence of vested
commercial interests that may push for quick rollout and be
more concerned with growing markets than improving global
health [37]. The regulation of mHealth products would also
help to minimize privacy violations through malware or other
computer-based viruses. The development of a Web-based
approval system for verifying the quality of mHealth apps, such
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as the Health on the Net Foundation Code of Conduct, or
National Health Service app stores, such as the United Kingdom
Health Apps Library, may be useful for ensuring the quality of
mHealth apps.
Regulators will also need to deal with the increasingly globalized
nature of mHealth research. Traditional processes of institutional
ethics approval and recruitment provide significant barriers to
conducting mHealth research that crosses national borders and
involves numerous agencies. Ethical oversight of mobile phone
research will need to evolve in order to allow it to happen, and
to prevent it from being done with insufficient ethical oversight
by commercial entities (eg, Apple, Facebook, Google). Failure
to do so may leave these companies with a vastly superior
understanding of health and behavior than researchers,
governments, and policy makers. Unlike publicly funded
research, these findings will be protected by
commercial-in-confidence and trade secrets laws.
Conclusions
Mobile phones and other remote monitoring devices have the
potential to provide researchers with access to unprecedented
volumes of clinically relevant data on patients’ quality of life
and psychosocial functioning, movement at home, in the
community, and social integration. Neurologists and other
treating clinicians will get real-time measures of disease
progression and the impact of medication over periods not
previously possible. The promise of this technology—the ability
to collect, analyze, and communicate vast amounts of personal
data almost immediately to research and clinical teams—also
poses new and unique ethical and technical challenges that need
to be managed if we are to realize the promise while minimizing
potential risks of harm. While the ethical issues of privacy,
consent and equity are not unique to mHealth, specific solutions
are needed that address the particular ethical challenges raised
my mobile phone technologies. The development of mobile
phone apps that optimally address these challenges will require
early and ongoing engagement with patients and other relevant
stakeholders.
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